This is a mobile optimized page that loads fast, if you want to load the real page, click this text.

MSB - Mesoblast Limited

Jump to new
I told myself to Buy more when they did the Capital raising a few months ago. But was to busy.
Really unsure what to make of this recent rise though.
 
My pick this month.
Possibly of good news soon and also being looked at as a possible treatment to help survival from Conav19.
 
Melbourne, Australia; Thursday April 9, 2020; and New York, USA; Wednesday April 8, 2020:

Mesoblast Limited (ASX:MSB; Nasdaq:MESO) today announced that its allogeneic mesenchymal stem cell (MSC) product candidate remestemcel-L will be formally evaluated in a randomized, placebo-controlled trial in 240 patients with acute respiratory distress syndrome (ARDS) caused by coronavirus infection (COVID-19).

This multi-center Phase 2/3 trial will be conducted as a public-private partnership in a collaboration with the Cardiothoracic Surgical Trials Network (CTSN), which was established by the United States National Institutes of Health’s National Heart, Lung and Blood Institute (NHLBI) as a flexible platform for conducting collaborative trials. Mesoblast holds an Investigational New Drug (IND) Application from the United States Food and Drug Administration (FDA) for use of remestemcel-L in the treatment of patients with COVID-19 ARDS, and will provide investigational product for the trial.
 
Also listed on Nasdaq, should be interesting tonight!
 
Not having sufficient reserves for a long-term hold, I grabbed a modest bundle today, basically for short-term opportunism - on the theory that a strong showing for the MESO listing on NASDAQ tonight will put a bomb under the MSB on ASX.
At a time when every man and their monkey is cranking out ASX announcements about some COVID-19 related benefit of their product, today's announcement from Mesoblast - while not a double-blind "proper" clinical trial - nevertheless has the prospect of serious benefit.

Looks like @Knobby22 's persistence choice of MSB for the tip of the month is about to come home to roost!

Today's close: $2.73, up almost %40. Not bad for a company with a market cap of $1 billion (and that was before today - now about $1.4 billion).

Rgrds, P
 
Promising results the treatment has had so far but am I reading it correctly that there were only 12 participant patients in the trial? If so, that seems a very small number to base this huge explosion on. Is it "statistically significant"? Any stataticians here?
 
Another disturbing line

Patients received a variety of experimental agents prior to remestemcel-L.

So which one ?
 
Purple XS2 said:
on the theory that a strong showing for the MESO listing on NASDAQ tonight will put a bomb under the MSB on ASX.

Rgrds, P
Click to expand...

Nasdaq - Meso
$11.00
$4.59 +71.16%
Before Hours Volume: 15.7K

Previous Close: $6.45

Looking good.
Volume now picking up as US wakes up :44.9k
 
Last edited:

"remestemcel-L will be formally evaluated in a randomized, placebo-controlled trial in 240 patients with acute respiratory distress syndrome (ARDS) caused by coronavirus infection (COVID-19)."

https://www.asx.com.au/asxpdf/20200409/pdf/44gv4hd8fxcwc1.pdf

I'm no Statistician. That will be across 20 hospitals I assume.
 
Statistically these types of announcements are BS but the jump is real, good on @Knobby22
As long as noone expects this to be the next csl, at least take some profit before the next bad news crashing it,or better observe the money flow of the people in the know
 
It isn't the next CSL but it is capable of being profitable soon.
The cell technology being used acts as an antiinflamatory like cortosoids. It is already selling in Japan as a pediatric treatment for kids unresponsive to cortosoids (acute graft host disease) and is being approved around the world.

The same treatment can be used in different medical fields hence the phase 3 trials for heart failure and lower back pain, results ecpected next few months.

At late stage Covid19 the immune response kills. It is logical this treatment will work. The anti malaria drug works a little the same way. I am quietly confident.
Obviously scientists think this is a goer hence the phase 2/3 trial being rolled out.
This could be approved fairly quickly and save a lot of lives.

However there are other similar cell cultures around and so big pharmaceutical companies can follow the MSB path and even CSL is doing so with acute graft host disease disease. The company is cash flow negative so a raising may occur at some stage.

Still I expect a bright future over the next few years.
 
Last edited:
Not a bad day on the NASDAQ, up over 200% at one stage. The enthusiasm was expected over there as they are tending to look for a miracle cure (like Trump suggesting antiseptic injections), but the reaction is more than a little overdone.

 
Nah, not yet.
I reckon Trump will talk it up, triple from here (fingers crossed). I want a 10 bagger.
 
my reply was just the covid19 reaction..not rational but who says the market is;
They may succeed on the ong term
Been in and out for so long, years, trouble is there is so much push and pump followed by raising I can not swallow it anymore, but for day trading why not
 
I think of it as long term investing with the eye to trading where the market overshoots.
 
From MSB website -
Mesoblast is using its proprietary mesenchymal lineage cell technology platform to develop and commercialize innovative allogeneic cellular medicines to treat complex diseases where inflammation plays a central role and are resistant to conventional standard of care.

The Company’s broad portfolio of late-stage product candidates are:

  • RYONCIL™ (remestemcel-L) for steroid-refractory acute graft versus host disease (acute GVHD) in children
  • REVASCOR® for advanced chronic heart failure
  • MPC-06-ID for chronic low back pain due to degenerative disc disease
Mesoblast’s Biologics License Application (BLA) for RYONCIL for the treatment of children with steroid-refractory acute GVHD has been accepted for priority review by the United States Food and Drug Administration (FDA). The FDA has set a Prescription Drug User Fee Act (PDUFA) action date of September 30, 2020, and if approved, Mesoblast will make RYONCIL immediately available in the United States.

Remestemcel-L is also being developed for rare diseases in adults and children. Additionally, Mesoblast has a promising emerging pipeline of Phase 2 product candidates and next generation technologies.

On 24th April 2020 announcement from MSB -
Melbourne, Australia; April 24, 2020; and New York, USA; April 23, 2020: Mesoblast Limited (ASX:MSB; Nasdaq: MESO) today announced 83% survival in ventilator-dependent COVID-19 patients (10/12) with moderate/severe acute respiratory distress syndrome (ARDS) treated during the period March-April 2020 with two intravenous infusions of Mesoblast’s allogeneic mesenchymal stem cell product candidate remestemcel-L within the first five days. 75% (9/12) have successfully come off ventilator support at a median of 10 days. At this time, seven have been discharged from the hospital. Patients received a variety of experimental agents prior to remestemcel-L. All patients were treated under an emergency Investigational New Drug (IND) application or expanded access protocol at New York City’s Mt Sinai hospital. In contrast, only 9% (38/445) of ventilator-dependent COVID-19 patients at a major referral hospital network in New York City were able to come off ventilator support when treated with standard of care during March/April 2020.1 Moreover, there was 88% mortality with only 12% survival (38/320) among ventilator-dependent COVID19 patients at a second major referral hospital network in New York City during the same period.2 These poor outcomes are consistent with earlier published data from China where mortality rates of over 80% were reported in patients with COVID-19 and moderate/severe ARDS.3 Mesoblast Chief Executive Dr Silviu Itescu stated: “The remarkable clinical outcomes in these critically ill patients continue to underscore the potential benefits of remestemcel-L as an anti-inflammatory agent in cytokine release syndromes associated with high mortality, including acute graft versus host disease and COVID-19 ARDS. We intend to rapidly complete the randomized, placebo-controlled Phase 2/3 trial in COVID-19 ARDS patients to rigorously confirm that remestemcel-L improves survival in these critically ill patients.” Mesoblast Chief Medical Officer Dr Fred Grossman said: “There is a significant need to improve the dismal survival outcomes in COVID-19 patients who progress to ARDS and require ventilators. We have implemented robust statistical analyses in our Phase 2/3 trial as recommended by the US Food and Drug Administration (FDA) in order to maximize our ability to evaluate whether remestemcel-L provides a survival benefit in moderate/severe COVID19 ARDS.”

Iggy
 
You must log in or register to reply here.

Similar threads

Can you make money investing in watches?
2
Replies
29
Views
1K
moXJO
M
XJO, Gear, Spi, Overwrites & CC's (no not the chips)
2
Replies
21
Views
3K
Rosscoe62
Multiculturalism
Replies
3
Views
592
Captain_Chaza
SGD - Snowline Gold Corp. (TSX-V)
Replies
1
Views
466
mullokintyre
GMIN - G Mining Ventures Corp. (TSX)
Replies
1
Views
592
mullokintyre
Menu
Log in
Register
Cookies are required to use this site. You must accept them to continue using the site. Learn more...